Showing results (151-160 of 167) with videos related to
Sort By:
Pageof 17
Oncogene|November 24, 2015
p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cellsJ M Bailey, A M Hendley, K J Lafaro, et al.Epilepsia|January 14, 2010
Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the ratMikhail Kalinichev, Andrea Bradford, Silvia Bison, et al.CNS & Neurological Disorders Drug Targets|August 22, 2006
Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockadeMartyn D Wood, Claire Scott, Kirsten Clarke, et al.The British Journal of Psychiatry : the Journal of Mental Science|May 17, 2018
Treatment-resistant depression and peripheral C-reactive proteinSamuel R Chamberlain, Jonathan Cavanagh, Peter de Boer, et al.The Journal of Physical Chemistry. A|July 15, 2015
Electronic State Spectroscopy of Halothane As Studied by ab Initio Calculations, Vacuum Ultraviolet Synchrotron Radiation, and Electron Scattering MethodsF Ferreira da Silva, D Duflot, S V Hoffmann, et al.Psychopharmacology|September 17, 2008
Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the ratM L Woolley, K A Waters, J E Gartlon, et al.British Journal of Pharmacology|December 24, 2016
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulatorSimon E Ward, Paul Beswick, Novella Calcinaghi, et al.Psychopharmacology|September 3, 2008
Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040Eric Southam, Jackie Cilia, Jane E Gartlon, et al.Journal of Proteome Research|April 30, 2009
Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortexDan Ma, Man K Chan, Helen E Lockstone, et al.European Journal of Pharmacology|November 3, 2009
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristicsLee A Dawson, Christopher J Langmead, Adeshola Dada, et al.Pageof 17